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Introduction
Therapeutic human papillomavirus (HPV) vaccines targeting the 
E6 and/or E7 HPV oncogenes were mainly designed to induce 
specific cytotoxic T lymphocyte (CTL) responses against cervical 
cancer, the second leading cause of cancer deaths in women world-
wide.1 Despite impressive results in animal models, their applica-
tion in humans has shown modest clinical effectiveness (reviewed 
in ref. 2). We have recently reported that the combination of anti-
gen-specific vaccination followed by the induction of local inflam-
mation by intravaginal (IVAG) instillation of Toll-like receptor 
(TLR) agonists (i.e., CpG oligonucleotides, CpG, a TLR9 agonist 
or poly(I:C), PIC, a TLR3 agonist) is able to promote the accu-
mulation of both total and antigen-specific CTLs in the genital 
mucosa (GM) of mice.3 Most interestingly, repeated IVAG CpG 
instillations after E7-targeting vaccination eventually led to the 
regression of large genital HPV-induced tumors. GM-localized 
CD8+ T cells recruited in response to CpG preferentially expressed 
CCR5 and CXCR3 chemokine receptors and E-selectin ligands, 
suggesting that they accumulated in the GM through the interac-
tion with CpG-induced CCL5, CCL3, CCL4, CXCL9, CXCL10, 
CXCL11 and/or E-selectin.3 Other TLR ligands are known to 
modify the expression of selectins, integrins, chemokines and che-
mokine receptors, which may affect T-cell migration to effector 
sites.4 Among these, live bacteria, such as Salmonella, can induce 
pro-inflammatory responses via bacterial components, including 
lipopolysaccharide (LPS, a TLR4 agonist),5 flagellin (a TLR5 
agonist)6 and/or bacterial DNA (TLR9 agonist), not only when 
delivered orally (their normal route of infection), but also when 
administered in vagina.7 In addition, attenuated Salmonella can 
be easily engineered to deliver heterologous antigens8,9 and is used 
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as a vaccine (strain Ty21a,10 Vivotif®) against typhoid fever by the 
oral route since decades, with an excellent safety record.11 Here, we 
have investigated whether attenuated Salmonella enterica serovar 
Typhimurium vaccine strains would act as an IVAG immunos-
timulant after E7 vaccination in mice.
Result and Discussion
Intravaginal instillation of live attenuated Salmonella enterica 
serovar Typhimurium after a subcutaneous (s.c.) E7 vaccination 
increased E7-specific effector CD8+ T cells in the cervix-vagina 
(CV). All C57Bl/6 mice were first synchronized in a diestrus-
like status to avoid possible variations in the IVAG immunos-
timulatory activity along the estrous cycle. Groups of mice were 
s.c. immunized with a long synthetic E7 peptide together with 
adjuvants12 and 5 d later PBS (as control), CpG or ~5 × 108 CFU 
of PhoPc attenuated Salmonella expressing an irrelevant antigen 
(PhoPckanL1S)13 were administered in vagina. Mice were sacri-
ficed at day 9, and cells recovered from CV were analyzed (Fig. 1) 
by ex-vivo interferon γ (IFNγ) ELISPOT assays using the H-2Db 
restricted E7
49–57
 CTL peptide.12 As previously shown,3 IVAG CpG 
significantly increased (by ~5-fold) E7-specific effector CD8+ T 
cells in the CV (means ± SEM, E7-specific IFNγ-secreting cells/105 
CV cells of 71 ± 8 as compared with 14 ± 5 after intravaginal PBS, 
p < 0.0001 by one-way ANOVA and Tukey’s post-test). More 
interestingly, intravaginal PhoPc was even more efficient, lead-
ing to a ~15-fold increased number of E7-specific IFNγ-secreting 
cells/105 CV cells (196 ± 46, p < 0.0001 and p < 0.05, as com-
pared with intravaginal PBS and intravaginal CpG, respectively). 
The PhoPc strain has a mutation in the two-component regula-
tory system phoP/phoQ, which controls more than 40 different 
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, Fig. 2A) expressing, under the prokaryotic trc pro-
moter, non-oncogenic forms of E7 (E7
Δ21–26
)17 and E6 (E6
Δ118–122
)18 
fused to the heat-shock protein (Hsp)70 of Mycobacterium tuber-
culosis (mt) (see lanes HspE7E6 in Fig. 2B).19,20 However, the 
IVAG administration of the E7-expressing PhoPc (PhopcE7) 
bacteria following E7 vaccination was only slightly more effi-
cient than PhoPc bacteria at increasing the number of E7-specific 
IFNγ-secreting cells in the CV (191 ± 42 and 167 ± 29 at day 
9, respectively, p = non significant, Fig. 2C). Even when exam-
ined at a later time point (day 15) to accommodate possible local 
antigen-presentation and specific T-cell proliferation variations, 
no significant difference between the two intravaginal recombi-
nant Salmonella strains could be observed (39 ± 11 and 32 ± 5, 
respectively, Fig. 2C). A subset of CV cells from day 9 (n = 4) were 
also examined by flow cytometry upon anti-CD8 and tetramer 
staining (TetE7, based on the H-2Db restricted E7
49–57
 CTL pep-
tide, see Table 1). A slightly higher number of TetE7+CD8+ cells 
was again observed upon IVAG PhoPcE7, as compared with IVAG 
PhoPc (p = non significant), but, more interestingly, the percent-
age of TetE7 CD8+ T cells among total CD8+ T cells appeared 
significantly higher than after the instillation of IVAG PhoPc bac-
teria (p < 0.001) or IVAG PBS (p < 0.05). The fact that E7-specific 
CD8+ T cells were enriched in the CD8+ T-cell population of the 
GM when IVAG Salmonella expressed E7 suggests that indeed 
some local boosting had occurred. This is in agreement with pre-
vious reports on the ability of recombinant PhoPc cells to induce 
antigen-specific antibodies and cell-mediated immune responses 
after IVAG immunization,7,21 although the modest effect observed 
in our case suggest that the expression of E7 was too low or not 
enough immunogenic in our recombinant PhoPc strain after a sin-
gle IVAG instillation. Indeed, PhoPcE7 bacteria were also unable 
to prevent tumor implantation when used as a vaccine in a pro-
phylactic setting (data not shown). Given the accumulating suc-
cess of Salmonella as gene delivery system,22 new constructs using 
an eukaryotic promoter for E7 expression would be worth test-
ing. Interestingly, and despite of the fact that PhoPc bacteria are 
surviving for three weeks in the CV at 104 CFU,7 the E7-specific 
response was greatly decreased at day 15, as compared with day 
9 (p < 0.01), though it was still significantly higher than after 
the IVAG administration of PBS (p < 0.05). This may suggest 
that an IVAG dose of 104 CFU is not sufficient to maintain a 
high number of E7-specific CD8+ T cells in the CV or, on the 
contrary, that the chronic presence of bacteria is counterproduc-
tive. In the case of CpG, three consecutive IVAG doses adminis-
tered at days 6, 9 and 12 were able to sustain a high E7-specific 
immune response until day 15, while successive PIC instillation 
were ineffective.3 The analysis of peripheral blood mononuclear 
genes required for intracellular survival and resistance to innate 
immune defense mechanisms.14,15 We thus further tested a dif-
ferently attenuated auxotrophic mutant Salmonella strain, AroA 
(AroAkanL1S),13 which depends on p-aminobenzoic acid and 
2,3-dihydroxybenzoate for the synthesis of aromatic amino acids 
and growth.16 IVAG AroA after E7-vaccination also significantly 
increased E7-specific IFNγ-secreting cells/105 CV cells (95 ± 12, 
p < 0.0001 as compared with intravaginal PBS, p = non significant 
as compared with PhoPc). Because these bacteria can persist in the 
CV after intravaginal infection,7 we tested whether viability was 
influencing their intravaginal immunostimulatory ability. Indeed 
intravaginal heat-killed (HK) AroA bacteria were still able to sig-
nificantly increase E7-specific IFNγ-secreting cells/105 CV cells 
(45 ± 7, p < 0.01 as compared with intravaginal PBS), though less 
efficiently than live AroA cells (p < 0.05 by Student’s t-tests).
Bacterial expression of E7 modestly improved the recruit-
ment of E7-specific CD8+ T cells in the cervix-vagina upon 
IVAG instillation. We wondered whether the expression of E7 by 
IVAG bacteria may further increase the recruitment of E7-specific 
CD8+ T cells in the CV by locally boosting vaccine-specific 
immune responses. For this purpose, we engineered a PhoPc strain 
Figure 1. IVAG phopc or AroA bacteria administered after e7 
immunization increased e7-specific effector CD8+ t cells in the cervix-
vagina. Groups of mice were s.c. immunized with 50 μg e71–98 + 10 μg 
CpG + 0.4 μg Escherichia coli heat labile toxin (e7 vaccine)12 and 5 days 
later instilled in vagina with pBS, 100 μg CpG, ~5x 108 CfU of phopc, 
AroA or heat-killed (HK) AroA bacteria. Mice were sacrificed three days 
later and cells recovered from the cervix-vagina were analyzed by ex 
vivo IfNγ eLISpOt as previously described.12 the numbers of e749–57 
specific IfNγ-secreting cells/105 cells are indicated. Horizontal bars 
represent mean responses. Significant differences are indicated by 
*p < 0.05, **p < 0.01 and ***p < 0.001 following one-way ANOVA and 
tukey’s post test (Graphpad prism 5).
Table 1. tete7 CD8+ and total CD8+ t cells in the genital mucosa (n = 4) after IVAG instillation of phopc bacteria expressing or not e7
IVAG immunostimulant TetE7+CD8+† Total CD8+ T cells† % TetE7+CD8+/total CD8+†
pBS 0.12 ± 0.04  0.66 ± 0.19 17.4 ± 0.4
phopc 1.83 ± 0.43*** 10.94 ± 3.06*** 16.9 ± 0.9
phopce7 2.28 ± 0.31*** 9.57 ± 0.92*** 22.6 ± 0.8*,¶¶
†Mean percentages ± SeM; *p< 0.05 as compared to IVAG pBS; *** p< 0.001as compared to IVAG pBS; ¶¶p< 0.001 as compared to IVAG phopc.
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was measured for total CD8+ T cells (Table 1). This confirms 
that IVAG Salmonella after E7 vaccination mainly promote the 
recruitment of CD8+ T cells, including E7 vaccine-specific cells, 
from the periphery. The chemokines and/or selectines involved in 
this process will have to be investigated. However, it is noteworthy 
that, similarly to CpG, Salmonella enterica serovar Typhimurium 
can induce the upregulation of CCL3, CCL4, CXCL9, CXCL10, 
CXCL11 and E-selectin in the intestinal mucosa.23,24 The fact that 
both CCL5 and CXCL10 are secreted by macrophages and den-
dritic cells upon Salmonella infection, while purified LPS or fla-
gellin were less efficient in this respect,25 may support our finding 
that live bacteria are superior immunostimulants than purified 
bacterial components. The ligands of CXCR3 and CCR5 report-
edly increase in the GM 24h after IVAG infection with PhoPc 
and/or AroA bacteria, returning to steady-state levels 6 days later,7 
which may possibly correlate to the decreased T-cell recruitment 
we observed at day 15.
In conclusion, our data show that the IVAG instillation of 
Salmonella vaccine strains after vaccination can lead to a major 
cells (PBMCs), spleen and lymph node draining the genital tract 
(GLN) (Table 2) confirms that the effect of IVAG bacteria on 
E7-specific CD8+ T-cell recruitment was restricted to the GM, as 
similar or rather lower number of E7-specific IFNγ-secreting cells 
were measured among PBMCs as well as in the GLN and spleen. 
Our flow cytometry analysis also indicates that the percentage 
of TetE7+ CD8+ cells in the CV of E7-vaccinated mice that had 
received IVAG PhoPc or PhoPcE7 cells were increased ~15-fold as 
compared with IVAG PBS instillation and a similar fold-increase 
Figure 2. Bacterial expression of e7 modestly influenced the fold-increase of e7-specific CD8+ t cells in the cervix-vagina upon intravaginal instillation. 
(A) the plasmid pfSnsd-kan3-mtHsp70HpV16e7
Δ21–26e6Δ118–122 contains within the NcoI and HindIII restrictions sites, instead of L1S,
13 a sequence encom-
passing the full lenght Mycobacterium tuberculosis (mt) heat-shock protein 70 (Hsp70) open reading frame (Orf) fused to the e7 Orf deleted from resi-
dues 21 to 26 and the e6 Orf deleted from residues 118–122. (B) expression of the fusion protein (~100 kDa) in phopc bacterial lysates (lane Hspe7e6) 
is detected with polyclonal anti-e7 and anti-e6 antibodies (kindly provided by Dr. John Schiller, NCI, Bethesda, USA) as well as with a monoclonal 
anti-mtHsp70 antibody (Hytest Ltd, turku, finland). for comparison, e7 and e6 only are detected in bacterial lysates from phopc cells expressing an 
e7-e6 fusion without Hsp70 (~32 kDa). (C) Mice s.c. immunized with the adjuvanted e7 vaccine and receiving 5 days later intravaginal pBS, CpG, phopc 
or phopce7 cells were sacrificed at day 9 (left) or at day 15 (right) and cells recovered from cervix-vagina were analyzed by ex vivo IfNγ eLISpOt. the 
numbers of e749–57-specific IfNγ-secreting cells/10
5 cells are indicated. Horizontal bars represent mean responses. Significant differences are indicated 
by *p < 0.05 and ***p < 0.001 following one-way ANOVA and tukey’s post test (Graphpad prism 5).
Table 2. Systemic e7-specific IfNγ-secreting cells /105 cells at day 9
IVAG immunostimulant PBMC† Spleen† GLN†
pBS 296 ± 87 164 ± 32 24 ± 10
CpG 417 ± 82 103 ± 20 41 ± 8
phopc 159 ± 53  59 ± 14* 26 ± 8
phopce7 108 ± 15  86 ± 19 22 ± 6
†Means ± SeM; *p< 0.05 as compared to intravaginal pBS.
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increase in vaccine-specific CD8+ T cell selectively in the GM, 
adding to the list of TLR agonists that may be used for cancer 
therapy.26 Further experiments are needed to unravel the under-
lying mechanisms and determine the effects of this strategy on 
genital HPV-associated tumor regression. Interestingly, our 
preliminary data (not shown) suggest that bacterial immunos-
timulation may be useful for tumors located in other mucosal 
sites. As Salmonella appears to exert a multipronged antineo-
plastic effect,27 the detailed characterization of these bacteria 
as local immunostimulants and antigen-delivery systems is 
warranted.
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